Products & ReviewClinical Diagnostics

therascreen FGFR RGQ RT-PCR Kit

therascreen  FGFR RGQ RT-PCR Kit - For qualitative detection of actionable alterations in the FGFR3 gene.

QIAGEN

The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our  Product Directory.

Ease of Use
After Sales Service
Value for Money
Write your own review

For qualitative detection of actionable alterations in the FGFR3 gene

  • FDA-approved FGFR alteration assay
  • Detection of four point mutations and two fusions in the FGFR3 gene
  • High sensitivity and specificity
  • Simple workflow with next-day results
  • Automated data analysis using Rotor-Gene AssayManager v2.1 software

The therascreen FGFR RGQ RT-PCR Kit is a qualitative in vitro diagnostic test for the detection of two point mutations in exon 7 [p.R248C (c.742C>T), p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3:TACC3v1 and FGFR3:TACC3v3) in the FGFR3 gene.

The therascreen FGFR RGQ RT-PCR Kit is the only FDA-approved companion diagnostic (CDx) test for the identification of patients with cases of urothelial cancer (UC) that harbor these actionable FGFR alterations, and for whom treatment with BALVERSA (erdafitinib) is indicated.

Product Overview

Links